Contract development manufacturer of nanomedicines, Ardena, has joined forces with mRNA and LNP technology specialists RiboPro, to form a new strategic commercial alliance.
Meissa Vaccines, a clinical-stage biotech company developing vaccines to prevent viral respiratory infections, has entered into a manufacturing agreement with contract research development organization (CRDMO) Exothera.
The EMA looks to the future by posting its five key priorities to address in the coming five years, which includes the need to recruit expertise in ‘novel manufacturing technologies’.
